What the Ovarian Cancer Research Alliance offers patients

The Ovarian Cancer Research Alliance, known as OCRA, describes itself as the largest global nonprofit that both funds ovarian cancer research and supports patients directly. That combination shapes everything about the organization. It is not purely a research funder, and it is not purely a support group. It tries to do both.

OCRA's scope is also broader than its name suggests. Its programs cover gynecologic cancers as a group, including cervical, endometrial, uterine sarcoma, vaginal, and vulvar cancers, alongside ovarian cancer.

If you or someone you love has just been diagnosed, several OCRA programs are built for exactly that moment.

• Woman to Woman Peer Mentor Program. Pairs you with someone who has faced a similar diagnosis.
• Steps 1:1 Counseling. One-on-one counseling support named specifically on OCRA's site.
• Staying Connected Support Series. Roundtables and workshops for ongoing connection.
• Patient Support Team. A contact point for patients who need to talk to someone directly.
• Webinars. Recorded and live sessions on treatment and living with a gynecologic cancer diagnosis.

These programs exist because a diagnosis is disorienting, and OCRA's stated approach is to pair medical information with a human connection rather than offering one without the other.

Beyond emotional support, OCRA offers a few concrete tools.

A Find a Doctor locator helps you search for gynecologic oncology specialists. A Free Genetic Testing Program is listed on the site for eligible patients, which matters because inherited mutations affect treatment choices in ovarian cancer. A Clinical Trial Navigator helps you search trials that might match your diagnosis.

For research participation, OCRA runs Living Lab, a patient registry for people diagnosed with ovarian or uterine cancer, plus a newer initiative described as an AI-powered research exchange connecting patients with researchers.

OCRA does not diagnose or treat anyone. Its doctor locator points you toward specialists; it does not vet or guarantee the quality of any individual physician's care, and the final choice of who treats you is yours.

Its genetic testing program and counseling services are described on the site, but eligibility rules, cost, and availability are not fixed facts you can rely on indefinitely. Nonprofit programs like these can be limited in scope or paused, so confirm current details before counting on any one of them.

And joining Living Lab or the clinical trial navigator does not enroll you in treatment or a study. These are information and research tools. Any actual clinical trial has its own eligibility criteria set by that trial's research team, independent of OCRA.

If you were diagnosed with a less commonly discussed gynecologic cancer, such as vulvar or vaginal cancer, it is worth knowing that OCRA's programs are not limited to ovarian cancer by name only. The organization explicitly includes these cancers in its mission, which means its peer mentor program, counseling, and support series may have more relevant material and connections than a purely ovarian-focused search would suggest.

If you are newly diagnosed, a reasonable starting point is the Patient Support Team contact, since a real person can help direct you to the specific program that fits your situation rather than you guessing among several options.

If you are already established with a gynecologic oncologist and are looking for research options, the clinical trial navigator and the genetic testing program are the more targeted tools.

Either way, treat OCRA as a source of connection and information layered on top of your medical team, not a replacement for it. Program details, phone numbers, and application requirements change, so check the current details on their site before you plan around any one resource.

OCRA also organizes an International Gynecologic Cancer Conference, bringing together researchers and clinicians working across this group of cancers. As a patient this is not somewhere you would typically attend, but it matters indirectly: it is one more sign that OCRA's role sits between funding new research and getting that research in front of the doctors who treat you, rather than delivering care itself.

If your own oncologist references newer approaches to ovarian or another gynecologic cancer, there is a reasonable chance that work traces back, at least in part, to research OCRA or a similar funder helped support. That connection does not change what you should do today, but it explains why an organization that does not treat patients is still worth knowing about.